Advertisement
New Zealand markets close in 4 hours 13 minutes
  • NZX 50

    11,859.70
    -7.88 (-0.07%)
     
  • NZD/USD

    0.5925
    -0.0004 (-0.07%)
     
  • NZD/EUR

    0.5528
    -0.0001 (-0.02%)
     
  • ALL ORDS

    7,837.80
    +5.90 (+0.08%)
     
  • ASX 200

    7,575.60
    +5.70 (+0.08%)
     
  • OIL

    79.19
    +0.19 (+0.24%)
     
  • GOLD

    2,334.10
    +23.10 (+1.00%)
     
  • NASDAQ

    17,318.55
    -122.14 (-0.70%)
     
  • FTSE

    8,121.24
    -22.89 (-0.28%)
     
  • Dow Jones

    37,903.29
    +87.37 (+0.23%)
     
  • DAX

    17,932.17
    -186.15 (-1.03%)
     
  • Hang Seng

    17,763.03
    +16.12 (+0.09%)
     
  • NIKKEI 225

    38,048.87
    -225.18 (-0.59%)
     
  • NZD/JPY

    92.3240
    +0.3550 (+0.39%)
     

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.

ADVERTISEMENT

Insulet (PODD)

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). It is worn on the body for approximately three days at a time and allows virtually pain-free automated cannula insertion and blood glucose meter integration.

PODD is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 12% year-over-year for the current fiscal year, with sales growth of 15.7%.

10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.54 to $3.08 per share. PODD also boasts an average earnings surprise of 100.1%.

On a historic basis, Insulet has generated cash flow growth of 69.6%, and is expected to report cash flow expansion of 71.7% this year.

PODD should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insulet Corporation (PODD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research